S100A4 and Miyoshi myopathy: The increased abundance of this protein in invasive versus non-invasive MM cell lines and invasive versus non-invasive MM tumors was consistent with reports of its higher expression in the peripheral leading edge of breast cancer [43], non-small-cell lung cancer (NSCLC) [44], and gain of S100A4/loss of membrane E-cadherin in cervical cancer with an unfavorable prognosis [8].